Protocolo diagnóstico y tratamiento de la enfermedad tromboembólica venosa
ISSN: 0304-5412
Argitalpen urtea: 2012
Zenbakien izenburua: Enfermedades de la sangre (III): enfermedades de la plaquetes y la coagulación
Saila: 11
Zenbakia: 22
Orrialdeak: 1366-1370
Mota: Artikulua
Beste argitalpen batzuk: Medicine: Programa de Formación Médica Continuada Acreditado
Laburpena
Venous thromboembolism (VTE) is the third most common cause of death from cardiovascular disease after heart attack and stroke. Sequelae after VTE include chronic pulmonary hypertension and post-thrombotic syndrome. The diagnosis of VTE is based on models of clinical probability, plasma D dimer and noninvasive imaging modalities (compression ultrasound or chest el). Most patients will respond to anticoagulation with parenteral unfractionated heparin or low molecular weight heparins, followed by oral vitamin K antagonists (sintrom or warfarin) during 3-6 months with coagulation monitoring of INR in the therapeutic range. Several novel oral anticoagulants are in development (dabigatran rivaroxaban, apixaban) which could replace vitamin K antagonists, since they are prescribed in fixed doses and do not need any coagulation monitoring.